Jove
Visualize
Contact Us

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: COVID‑19: The crucial role of blood coagulation and fibrinolysis.

Internal and emergency medicine·2020
Same author

COVID-19: The crucial role of blood coagulation and fibrinolysis.

Internal and emergency medicine·2020
Same author

Why include the humanities in medical studies?

Internal and emergency medicine·2019
Same author

Use and Misuse of Aspirin in Primary Cardiovascular Prevention.

Clinical Medicine Insights. Cardiology·2017
Same author

Error, contradiction and reversal in science and medicine.

European journal of internal medicine·2017
Same author

Biological Determinants of Fasting and Postload Plasma Homocysteine Levels in Healthy Italian Subjects.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2016
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 27, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet therapy: controversial aspects.

Sergio Coccheri1

  • 1Cardiovascular Medicine, University of Bologna, Italy. coccheris.angio@libero.it

Thrombosis Research
|November 29, 2011
PubMed
Summary
This summary is machine-generated.

Antiplatelet therapy shows consistent relative risk reduction but variable absolute benefits. Factors like drug interactions and genetics influence resistance, impacting treatment efficiency, especially in acute coronary syndromes.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Experiment Videos

Last Updated: May 27, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Research

Background:

  • Antiplatelet therapy is crucial for secondary and primary prevention of cardiovascular events.
  • Uncertainty exists regarding the uniform efficacy and efficiency of antiplatelet agents across diverse clinical scenarios.
  • Variability in patient response, termed 'resistance,' is a significant concern, particularly in high-risk conditions like acute coronary syndrome (ACS).

Purpose of the Study:

  • To explore the complexities of antiplatelet therapy efficacy and efficiency in both secondary and primary prevention.
  • To identify factors contributing to antiplatelet drug resistance and their clinical implications.
  • To evaluate the role of novel antiplatelet agents and diagnostic tools in optimizing treatment.

Main Methods:

  • Review of existing studies on antiplatelet therapy efficacy and resistance mechanisms.
  • Analysis of factors influencing aspirin and clopidogrel resistance, including drug interactions, genetic polymorphisms (COX1, CYP450), and platelet turnover.
  • Examination of 'High on Treatment Platelet Reactivity' (HTPR) and genetic testing as predictors of outcomes.
  • Consideration of newer antiplatelet agents (prasugrel, ticagrelor, vorapaxar) and their potential to overcome resistance.

Main Results:

  • Relative risk reduction with antiplatelets is generally uniform, but absolute risk reduction varies with patient risk levels, affecting treatment efficiency.
  • Factors like non-compliance, NSAID interference, diabetes, and rapid platelet turnover contribute to aspirin resistance.
  • Clopidogrel resistance is linked to drug interactions, diabetes, increased platelet turnover, and CYP450 polymorphisms.
  • HTPR and genetic testing show predictive value for outcomes in some ACS studies, but results are not universally confirmed.
  • Newer agents may offer improved resistance profiles.
  • In primary prevention, aspirin's efficiency is lower, with mixed results for net clinical benefit, though recent meta-analyses suggest a potential mortality benefit.

Conclusions:

  • Antiplatelet therapy's efficiency is highly dependent on individual patient risk stratification.
  • Understanding and addressing antiplatelet resistance through monitoring (HTPR) or genetic testing may aid in selecting high-risk ACS patients.
  • Novel antiplatelet drugs show promise in overcoming resistance.
  • The role of aspirin in primary prevention warrants further investigation, as recent data suggest a potential, albeit small, mortality benefit.